Alvimopan NDC 0254-3012

NDC codes

FDA NDC Directory

Product NDC (as listed)0254-3012Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00254-3012Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0254-3012-55	00254301255	6 BLISTER PACK in 1 CARTON (0254-3012-55) / 5 CAPSULE in 1 BLISTER PACKMarketed from May 3, 2023

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Alvimopan
Generic name (nonproprietary): alvimopan
Active ingredients: Alvimopan — 12 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Par Health USA, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 216843
Marketing start: May 3, 2023
Listing expires: Dec 31, 2027
Other FDA classes: Opioid Antagonists (Mechanism)
Identifiers: Product ID 0254-3012_d43941f1-7b52-4e7a-a560-9a8e28a7ac65SPL ID d43941f1-7b52-4e7a-a560-9a8e28a7ac65SPL set ID 1cd584de-b704-4d26-8451-e3247ffb8d08RxCUI 799835UNII 677C126AET
Pharmacologic class: Opioid Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400254301255 followed by a unit qualifier and the quantity

Package 00254-3012-55. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 2, 2024. This label includes a boxed warning.

Indications (excerpt from the label)

Alvimopan capsules are indicated to accelerate the time to upper and lower gastrointestinal recovery following surgeries that include partial bowel resection with primary anastomosis. Alvimopan capsules are an opioid antagonist indicated to accelerate the time to upper and lower gastrointestinal recovery following surgeries that include partial bowel resection with primary anastomosis. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)